Avitotamig Biosimilar Monoclonal Antibody (CD33) for Research

Cat No.: GMP-Bios-INN-1090

Anti-SIGLEC3/CD33/p67 therapeutic antibody (Pre-made Avitotamig biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Avitotamig (development code YMS-5A) is a bispecific antibody targeting CD33 and CD3. It is developed by Y-mAbs Therapeutics for acute myeloid leukemia. Further development details are under investigation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1090-1mg 1mg 3090
GMP-Bios-INN-1090-10mg 10mg
GMP-Bios-INN-1090-100mg 100mg
GMP-Bios-INN-1090-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Avitotamig biosimilar, Whole mAb, Anti-SIGLEC3/CD33/p67 Antibody: Anti-CD33/Myeloid cell surface antigen CD33/Sialic acid-binding Ig-like lectin 3 (Siglec-3)/gp67 therapeutic antibody
INN Name Avitotamig
Target SIGLEC3/CD33/p67
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended 2024
Companies Y-mAbs Therapeutics
Conditions Approved na
Conditions Active Acute myeloid leukemia
Conditions Discontinued na
Production na
Development Tech TBC